Precision Medicine in Myeloproliferative Neoplasms

Welcome to this podcast episode featuring Prof Claire Harrison (Clinical Director at Guy’s and St Thomas’ NHS Foundation Trust) and Prof Jean-Jacques Kiladjian (Professor at Université Paris-Diderot and Hôpital Saint-Louis).  Join them as they navigate the challenges and opportunities of precision medicine in MPNs, discover how advancements in molecular techniques are reshaping disease diagnosis, patient stratification and treatment tailoring.   Gain insights into the evolving landscape of targeted therapies for MPNs, including JAK inhibitors and emerging strategies for CALR mutation targeting.  Listen as our experts highlight the heterogeneity of clinical needs based on individual patients' molecular profiles and the promise of personalised treatment approaches bringing exciting prospects for improving patient outcomes in this dynamic field. Host: Isabel Olivera-Martinez, PhDGuest: Prof Claire Harrison and Prof Jean-Jacques KiladjianThis is the fourth episode in a series of podcasts covering precision medicine across various disorders; more podcasts will be available in the future. Stay tuned!Learn MoreIf you'd like to learn more about MPN, check out the EHA - Myeloproliferative Neoplasms Program  on EHA Campus.Interested in more content related to Precision Medicine? We've got you covered. Check out podcasts, clinical cases, courses, and more on EHA Campus.What did you think of this podcast? Share your opinions with us in this short feedback survey.Provide FeedbackWould you like to explore more eLearning or podcasts? Please visit the EHA Campus.https://ehaedu.org/CampusSubscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/Facebook: https://e-h-a.link/facebookLinkedIn: https://www.linkedin.com/company/eha/Email us: [email protected] to receive the EHA Educational Updates via https://eha.news/subscribe 

There are no comments yet.

Please log in to write the first comment.